false
--12-31
0001530766
0001530766
2025-09-10
2025-09-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 10, 2025
BioSig
Technologies, Inc.
(Exact
name of Registrant as Specified in its Charter)
| Delaware |
|
001-38659 |
|
26-4333375 |
(State
or other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2431
Aloma Avenue, Suite 243
Winter
Park, Florida 32792
(Address
of Principal Executive Offices) (Zip Code)
(203)
409-5444
(Registrant’s
Telephone Number, Including Area Code)
12424
Wilshire Blvd, Suite 745
Los
Angeles, California 90025
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
BSGM |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
September 10, 2025, BioSig Technologies, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate
of Incorporation (the “Certificate of Amendment”) to effect a change in the name of the Company from “BioSig Technologies,
Inc.” to “Streamex Corp.” (the “Name Change”). In addition, effective before the open of market trading
on September 12, 2025, the Company’s common stock will cease trading under the ticker symbol “BSGM” and will begin
trading on the Nasdaq Stock Market under the ticker symbol “STEX” (the “Symbol Change”). The aforementioned Name
Change and Symbol Change was approved by the Board of Directors of the Company.
The
Name Change does not affect the rights of the Company’s security holders. There will be no change to the Company’s CUSIP
in connection with the Name Change. Following the Name Change, existing stock certificates, which reflect the Company’s prior corporate
name, will continue to be valid. Certificates reflecting the new corporate name will be issued in due course as old stock certificates
are tendered for exchange or transfer to the Company’s transfer agent.
Pursuant
to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to complete the Name Change or to approve
or effect the Certificate of Amendment. The information set forth herein is qualified in its entirety by the reference to the complete
text of the Certificate of Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated by reference herein.
Item
7.01 Regulation FD Disclosure.
On
September 10, 2025, the Company issued a press release announcing the Name Change and Symbol Change. A copy of the press release is furnished
hereto as Exhibit 99.1 and incorporated by reference herein.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in
such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute
a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination
of such information is required by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. |
|
Description |
| 3.1 |
|
Certificate of Amendment of Amended And Restated Certificate Of Incorporation of BioSig Technologies, Inc. |
| 99.1 |
|
Press Release, dated September 10, 2025 |
| 104 |
|
Cover
Page Interactive Data File (embedded as Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
BIOSIG
TECHNOLOGIES, INC. |
| |
|
|
| Date:
September 11, 2025 |
By: |
/s/
Karl Henry McPhie |
| |
Name: |
Karl
Henry McPhie |
| |
Title: |
Chief
Executive Officer |
